Explore 3 Stock Ideas & Industry Insights Download Free Report

UK Technical Analysis Report

FTSE All-Share Traded is Trading Above 50- Period SMA: Two LSE Listed Stocks Gaining Upside Momentum –PRTC & CLX

Apr 14, 2026

  • PRTC:LSE
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (GBX)
  • CLX:LSE
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (GBX)

Company Overview: PureTech Health PLC (LON: PRTC) is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. Calnex Solutions PLC (LON: CLX) is a United Kingdom-based company, which designs, produces and markets test and measurement instrumentation and solutions for the telecoms and cloud computing industries. This Report covers the Price Action and Technical Indicators Analysis along with the Target Levels, Stop Loss, Support Levels, Resistance Levels, and Recommendations on these two stocks.

FTSE All-Share Index (.FTAS) Market Round-Up

Last week, the FTSE All-Share Index (.FTAS) closed at 5,664.45, gaining 1.76% for the week ended April 10th, 2026. Sentiment remained mixed as firmness in U.S. equities continued to influence global markets. However, British equities showed relative resilience, with selective participation supporting the index. Overall, the market reflected stability within a consolidation phase, with global cues influencing direction while domestic strength helped limit deeper downside.

From a technical perspective, the index continues to reflect a positive and resilient technical structure, holding above its rising trendline support despite the recent pullback from record highs. Prices remain comfortably above both the 21-period and 50-period Simple Moving Averages, reinforcing the strength of the broader uptrend, while the recovery back above the 21-period average indicates improving near-term momentum. The 14-period RSI near 61.18 suggests momentum remains positive without appearing overstretched. Overall, the setup remains constructive, with scope for further consolidation followed by a gradual continuation of the upward trend from current levels.

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites.  All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

Past performance is not a reliable indicator of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions